ArticleFrontiers in pharmacology2018
A Cell-Based Metabonomics Approach to Investigate the Varied Influences of Chrysophanol-8-O-β-D-Glucoside With Different Concentrations on L-02 Cells.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Identification of Efficacy-Associated Markers to DiscriminateMolecules (Basel, Switzerland) · 2023Article
- Innovative Application of Metabolomics on Bioactive Ingredients of Foods.Foods (Basel, Switzerland) · 2022Review
- Pharmacokinetics, Tissue Distribution, and Excretion Characteristics of a Radix Polygoni Multiflori Extract in Rats.Frontiers in pharmacology · 2022Article
- Changes of Lipopolysaccharide-Induced Acute Kidney and Liver Injuries in Rats Based on Metabolomics Analysis.Journal of inflammation research · 2021Article
- Contribution of anthocyanin pathways to fruit flesh coloration in pitayas.BMC plant biology · 2020Article
- Screening Bioactive Compounds of Siraitia grosvenorii by Immobilized βFrontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, the effects of different concentrations of chrysophanol-8-O-β-D-glucoside (C-8-O-β-D-glu) on L-02 liver cells were analyzed by high content analysis (HCA) and metabonomics to explore the potential mechanism involved. The results showed that low concentrations (12 and 24 μM) of C-8-O-β-D-glu increased the cells viability significantly, while high concentration (96 μM) showed significant cytotoxicity on L-02 cells. HCA was applied to analyze the changes of nuclei and mitochondria after the cells being exposed to C-8-O-β-D-glu for 24 h. The results showed high concentration (96 μM) of C-8-O-β-D-glu significantly reduced the number of living cells, increased average nucleus area, DNA content and mitochondrial membrane potential (MMP). Then non-target metabonomics was carried out to identify potential biomarkers and metabolic pathways of L-02 cells impacted by C-8-O-β-D-glu. Eleven important potential biomarkers associated with four metabolic pathways were identified in this analysis. Dysregulation of alanine, aspartate and glutamate metabolism were observed in both LCG and HCG. In addition, low concentration (24 μM) of C-8-O-β-D-glu would impact arginine and proline metabolism. High concentration (96 μM) of C-8-O-β-D-glu would impact phenylalanine metabolism and beta-alanine metabolism. Alanine, aspartate and glutamate metabolism, arginine and proline metabolism, phenylalanine metabolism, beta-alanine metabolism were involved in different effects of C-8-O-β-D-glu on L-02 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.